Zhejiang Huakang Pharmaceutical (605077) Stock Overview
Zhejiang Huakang Pharmaceutical Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
605077 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Zhejiang Huakang Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.50 |
| 52 Week High | CN¥20.20 |
| 52 Week Low | CN¥13.11 |
| Beta | 0.58 |
| 1 Month Change | -18.86% |
| 3 Month Change | -23.88% |
| 1 Year Change | -9.26% |
| 3 Year Change | -37.67% |
| 5 Year Change | n/a |
| Change since IPO | -50.31% |
Recent News & Updates
Recent updates
A Look At The Fair Value Of Zhejiang Huakang Pharmaceutical Co., Ltd. (SHSE:605077)
Dec 19
Zhejiang Huakang Pharmaceutical's (SHSE:605077) Anemic Earnings Might Be Worse Than You Think
Nov 02Zhejiang Huakang Pharmaceutical Co., Ltd.'s (SHSE:605077) Earnings Are Not Doing Enough For Some Investors
Oct 14Zhejiang Huakang Pharmaceutical (SHSE:605077) Will Want To Turn Around Its Return Trends
Sep 26Improved Earnings Required Before Zhejiang Huakang Pharmaceutical Co., Ltd. (SHSE:605077) Shares Find Their Feet
Jul 02Zhejiang Huakang Pharmaceutical (SHSE:605077) May Have Issues Allocating Its Capital
May 28We Think That There Are Some Issues For Zhejiang Huakang Pharmaceutical (SHSE:605077) Beyond Its Promising Earnings
May 02Shareholder Returns
| 605077 | CN Food | CN Market | |
|---|---|---|---|
| 7D | -5.8% | -1.4% | 0.3% |
| 1Y | -9.3% | -2.5% | 16.8% |
Return vs Industry: 605077 underperformed the CN Food industry which returned -2.5% over the past year.
Return vs Market: 605077 underperformed the CN Market which returned 16.8% over the past year.
Price Volatility
| 605077 volatility | |
|---|---|
| 605077 Average Weekly Movement | 3.9% |
| Food Industry Average Movement | 4.2% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 605077 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 605077's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Deshui Chen | www.huakangpharma.com |
Zhejiang Huakang Pharmaceutical Co., Ltd. engages in the research, production, and sale of polyols and starch sugar worldwide. It offers polyols products such as xylitol, is a polyol that occurs naturally regular sugar raise blood sugar levels; sorbitol, is produced by the catalytic hydrogenation of D-glucose and is available as a free-flowing crystalline powder, and as aqueous solutions; maltitol a bulk sweetener produced from naturally occurring compounds in corn; erythritol, is produced by the enzymatic hydrolysis of starch into glucose, non-caloric, non-hygroscopic excipient with excellent sweet taste and cooling effect; lactitol is produced by hydrogenation of lactose; mannitol is derived from enzymatic hydrolysis of starch; isomalt is produced from sucrose as a raw material and transformed into isomaltulose by sucrose isomerase. In addition, the company offers starch sugar provide high fructose, glucose, maltose syrups, maltodextrin; as well as rare sugar d- xylose, and l-arabinose; and dietary fiber include polydextrose.
Zhejiang Huakang Pharmaceutical Co., Ltd. Fundamentals Summary
| 605077 fundamental statistics | |
|---|---|
| Market cap | CN¥4.30b |
| Earnings (TTM) | CN¥249.95m |
| Revenue (TTM) | CN¥3.66b |
Is 605077 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 605077 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.66b |
| Cost of Revenue | CN¥3.02b |
| Gross Profit | CN¥642.58m |
| Other Expenses | CN¥392.63m |
| Earnings | CN¥249.95m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.84 |
| Gross Margin | 17.55% |
| Net Profit Margin | 6.83% |
| Debt/Equity Ratio | 95.9% |
How did 605077 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/14 06:05 |
| End of Day Share Price | 2025/12/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zhejiang Huakang Pharmaceutical Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Citic Securities Co., Ltd. |
| Zhe Wang | Citic Securities Co., Ltd. |
| Lin Yang | Guosen Securities Co., Ltd. |